225Ac‑PSMA‑617 radioligand therapy of de novo metastatic hormone-sensitive prostate carcinoma (mHSPC): preliminary clinical findings
225Ac-PSMA-617 has demonstrated good anti-tumor effect as a treatment option for metastatic castration-resistant prostate cancer (mCRPC) patients. No study has previously assessed treatment outcome and survival following 225Ac- PSMA-617 treatment of de novo metastatic hormone-sensitive prostate carcinoma (mHSPC) patients. Based on the potential side effects that are known and explained to the patients by the oncologist, some of the patients refused the standard treatment and are seeking alternative therapies. Thus, we report our preliminary findings in a retrospective series of 21 mHSPC patients that refused standard treatment options and were treated with 225Ac-PSMA-617.
SATHEKGE Mike;
BRUCHERTSEIFER Frank;
VORSTER Mariza;
LAWAL I;
MOKOALA K;
REED Janet;
MASEREMULE Letjie;
NDLOVU Honest;
HLONGWA Khanyi;
MAES A;
MORGENSTERN Alfred;
VAN DE WIELE C;
2023-10-25
SPRINGER
JRC134532
1619-7070 (online),
https://link.springer.com/article/10.1007/s00259-023-06165-9,
https://publications.jrc.ec.europa.eu/repository/handle/JRC134532,
10.1007/s00259-023-06165-9 (online),
Additional supporting files
| File name | Description | File type | |
|---|
